$19.17 -0.03 (-0.16%)
2/9/2010 4:00 PM

BioMarin Pharmaceutical, Inc. (BMRN)

CAPS Rating: 4 out of 5

The Company develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.

Current Price $19.17 Mkt Cap $1.93B
Open $19.74 P/E Ratio 41.67
Prev. Close $19.17 Div. (Yield) N/A (N/A)
Daily Range $18.97 - $20.24 Volume 2,043,457
52-Wk Range $9.93 - $21.50 Avg. Daily Vol. 0

BMRN News and Commentary

Caps

How do you think BMRN will perform vs the S&P 500?

Add Stock to Watchlist

All Members

862 Outperform
41 Underperform
 

All-Star Members

222 Outperform
10 Underperform
 

Wall Street

15 Outperform
1 Underperform
 

Top BMRN Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

topsecret09 (52.60)
Submitted October 02, 2009


BioMarin has developed and commercialized three products in ten years, a remarkable accomplishment in the biopharmaceutical industry, and a testament to the company’s passion and dedication to patients with serious, unmet medical needs.More

0 Comments | Reply | Report this Post

nonothing2 (< 20)
Submitted August 18, 2008

THis company is in a good market because Pharmeceuticals will always be needed, but a PE ration of 659 is simply unsustainable. A PE of above 40 is high, but this companies stock is over 600 times more expensive than its earnings per share. That's… More

1 Comment | Reply | Report this Post
BMRN VS S&P 500 (SPY)

Fools bullish on BMRN are also bullish on:

Fools bearish on BMRN are also bearish on:

Recent Community Commentary

Read the most recent pitches from members about BMRN.

Recs

0
Member Avatar JackCaps (< 20) Submitted: 1/21/2010 8:11:47 PM : Underperform Start Price: $20.61 BMRN Score: +3.41

A PE of 50 is a bit much for a company whose last 4 quarters had rather flat revenues.

Report this Post 0 Comments | Reply | Permalink

Recs

1
Member Avatar topsecret09 (52.60) Submitted: 10/1/2009 11:36:45 PM : Outperform Start Price: $17.70 BMRN Score: +3.20


BioMarin has developed and commercialized three products in ten years, a remarkable accomplishment in the biopharmaceutical industry, and a testament to the company’s passion and dedication to patients with serious, unmet medical needs.
BioMarin has three approved products on the market today:
•Kuvan® (sapropterin dihydrochloride) Tablets for PKU
•Naglazyme® (galsulfase) for MPS VI
•Aldurazyme® (laronidase) for MPS I The year 2008 was a very important milestone in BioMarin’s history. We achieved our first profitable full year, with total revenues up 144 percent from 2007 to nearly $300 million, and increased sales across all of our three products. We continue to build an exciting pipeline, with a clinical portfolio featuring PEG-PAL for PKU and GALNS for MPS IVA, and a preclinical lineup that provides hope to many other patients with a variety of other rare diseases.
The year also brought with it the U.S. launch of Kuvan and we have been encouraged by the progress made thus far in a market with unique complexities. We continue to look for new ways to enhance our commercial efforts in this area and we remain very optimistic about the long-term potential of the product.
Other successes throughout the year included several regulatory achievements such as the approval of Naglazyme in Japan and South Korea, and the recent approval of Kuvan secured in the European Union by our partner Merck Serono.
In 2008, BioMarin achieved important milestones that will fuel future growth opportunities in the orphan drug industry. Today, as a fully integrated mid-cap biopharmaceutical company with three products on the market, strong revenues and cash reserves of nearly $560 million, we are confident and well positioned for the long-term. In 2009, we will continue to advance our pipeline and actively pursue valuable business development opportunities to bring increased value to patients, shareholders and employees. Logical buyout candidate In the BIOTECH field,should reward shareholders Into the future... TS

Report this Post 0 Comments | Reply | Permalink

Recs

0
Member Avatar bestdamstockpkr (72.14) Submitted: 9/11/2009 7:26:46 AM : Outperform Start Price: $17.62 BMRN Score: +6.10

i usually don't by based soley on a recommendation without researching it my self, but I did this one. probably a mistake?

Report this Post 0 Comments | Reply | Permalink
View All 106 Pitches »

Leaderboard

Find the members with the highest scoring picks in BMRN.

Score Leader

stratton6

stratton6 (99.05) Score: +141.68

I like this company. I like their niche and seem to be well run.

Top
Pick 		Member Name Member
Rating 		Start
Date 		Call Time
Frame 		Start
Price 		Stock
Gain 		S&P
Gain 		Score Commentary
TMFBreakerCharly 99.20 4/27/2006 5/27/2009 Outperform 3Y $12.13 +58.04% -11.54% +69.57 2 Comments
BreakerBeth 91.63 5/17/2006 Outperform 5Y $12.26 +56.36% -10.67% +67.03 1 Comment
RBBioContest06 65.69 6/1/2006 Outperform 1Y $13.05 +46.90% -9.88% +56.78 1 Comment
DamYankee < 20 9/29/2006 Outperform 1Y $14.41 +33.03% -14.92% +47.96
MellieMel777 56.68 9/29/2006 Outperform 3Y $14.41 +33.03% -14.92% +47.96 1 Comment
mgaal < 20 4/30/2007 Outperform 1Y $16.16 +18.63% -24.25% +42.88
phytoremediation < 20 4/30/2007 Outperform 3M $16.16 +18.63% -24.25% +42.88 1 Comment
inthefield 57.60 4/30/2007 Outperform NS $16.16 +18.63% -24.25% +42.88
rolloro 44.73 10/2/2006 Outperform 3Y $15.00 +27.80% -14.76% +42.56 1 Comment
taxisvs 82.50 10/2/2006 Outperform NS $15.00 +27.80% -14.76% +42.56
View Complete Scorecard »

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating		 Start
Date		 Call Time
Frame		 Start
Price		 Stock
Gain		 S&P
Gain		 Score End Date Commentary
TrackRothCapital 80.39 2/9/2010 Outperform NS $19.74 -2.89% +0.08% -2.97
TrackCollinsStew 68.03 12/9/2009 Outperform NS $17.29 +10.87% -2.15% +13.03
TrackCreditSuiss 93.62 10/30/2009 Outperform NS $17.56 +9.17% +1.93% +7.24
TrackJimCramer < 20 9/16/2009 Underperform 3W $17.48 +9.67% +0.70% -8.97
TrackMorganJos < 20 4/21/2009 Outperform NS $12.26 +64.19% +37.50% +26.69 1/8/2010 @ $20.13
TrackFTNEquityCa 65.55 3/12/2009 Outperform NS $10.24 +87.21% +49.78% +37.43
TrackLeerinkSwan 92.83 3/12/2009 Outperform NS $10.36 +85.04% +50.25% +34.79
TrackRothCapital 80.39 2/24/2009 Outperform NS $12.09 +43.34% +44.83% -1.49 10/19/2009 @ $17.33
TrackBreanMurray 86.47 1/9/2009 Outperform NS $19.20 -1.51% +18.58% -20.09 2/8/2010 @ $18.91
TrackBenchmark 94.92 1/7/2009 Outperform NS $18.11 -26.28% -12.59% -13.69 2/19/2009 @ $13.35
TrackCitigroup 85.92 11/21/2008 Outperform NS $14.42 +32.94% +42.64% -9.70
TrackZacks 62.21 10/29/2008 Outperform 3M $18.01 -34.43% -17.74% -16.68 2/20/2009 @ $11.81 1 Comment
TrackWMBlair 69.55 9/12/2008 Outperform NS $27.29 -29.75% -11.01% -18.75
TrackCollinsStew 68.03 8/21/2008 Outperform NS $25.84 -48.33% -37.24% -11.09 2/19/2009 @ $13.35
TrackSoleil 93.91 8/6/2008 Outperform NS $29.06 -34.03% -13.52% -20.51
TrackUBS 87.99 7/25/2008 Outperform NS $31.78 -39.68% -12.28% -27.40
TrackJefferies 82.08 11/6/2007 Outperform NS $28.25 -32.14% -25.54% -6.60
TrackWellsFargo 80.02 10/11/2007 Outperform NS $27.34 -51.17% -49.00% -2.17 2/19/2009 @ $13.35
TrackCitigroup 85.92 9/28/2007 Outperform NS $24.14 +38.82% -11.38% +50.19 6/12/2008 @ $33.51
TrackZacks 62.21 8/9/2007 Outperform 3M $21.48 -5.07% -32.04% +26.96 10/20/2008 @ $20.39 1 Comment
TrackFerrisBaker 79.44 7/26/2007 Outperform NS $18.37 +4.35% -24.49% +28.85
TrackAGEdwards 93.04 2/16/2007 Outperform NS $20.30 -5.56% -21.78% +16.22
TrackRodmanRen < 20 12/19/2006 Outperform NS $16.82 +13.97% -19.53% +33.50
TrackBroadpoint.AmTech 76.97 10/10/2006 Outperform NS $16.09 +19.14% -15.77% +34.91
TrackRWBaird 87.00 10/2/2006 Outperform NS $15.00 +27.80% -14.76% +42.56
TrackJimCramer < 20 5/25/2006 Outperform 3W $13.00 +34.46% -16.67% +51.13 9/17/2009 @ $17.48

Featured Broker Partners